Antibody evolution immunogens
US10004800B2 · kind B2 · utility
3Cited by
0References
24Claims
0Family size
Assignees
- Duke University
- LOS ALAMOS NATIONAL SECURITY, LLC
- The Trustees of the University of Pennsylvania
- TRUSTEES OF BOSTON UNIVERSITY
- The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer
- The Board of Trustees of the Leland Stanford Junior University
Inventors
Key dates
| Filing date | Sep 12, 2013 |
| Grant date | Jun 26, 2018 |
| Priority date | — |
| Expiry date | Sep 12, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16134
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.